<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p144" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_144{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_144{left:306px;bottom:30px;}
#t3_144{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_144{left:346px;bottom:30px;}
#t5_144{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_144{left:517px;bottom:30px;}
#t7_144{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_144{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_144{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_144{left:1124px;bottom:27px;letter-spacing:0.2px;}
#tb_144{left:35px;bottom:777px;letter-spacing:0.18px;word-spacing:0.01px;}
#tc_144{left:35px;bottom:754px;letter-spacing:0.08px;word-spacing:0.11px;}
#td_144{left:35px;bottom:731px;letter-spacing:0.12px;word-spacing:-0.04px;}
#te_144{left:35px;bottom:707px;letter-spacing:0.07px;word-spacing:0.26px;}
#tf_144{left:35px;bottom:684px;letter-spacing:0.19px;}
#tg_144{left:236px;bottom:684px;letter-spacing:0.41px;}
#th_144{left:270px;bottom:684px;}
#ti_144{left:280px;bottom:684px;letter-spacing:0.27px;}
#tj_144{left:336px;bottom:684px;}
#tk_144{left:346px;bottom:684px;letter-spacing:0.24px;}
#tl_144{left:398px;bottom:684px;letter-spacing:-0.15px;word-spacing:0.33px;}
#tm_144{left:441px;bottom:684px;letter-spacing:0.24px;}
#tn_144{left:484px;bottom:684px;letter-spacing:0.13px;word-spacing:0.05px;}
#to_144{left:35px;bottom:661px;letter-spacing:0.06px;word-spacing:-0.83px;}
#tp_144{left:35px;bottom:638px;letter-spacing:0.18px;}
#tq_144{left:35px;bottom:614px;letter-spacing:0.08px;word-spacing:-0.03px;}
#tr_144{left:35px;bottom:591px;letter-spacing:0.13px;word-spacing:-0.67px;}
#ts_144{left:35px;bottom:568px;letter-spacing:0.02px;word-spacing:-1.07px;}
#tt_144{left:35px;bottom:545px;letter-spacing:0.07px;word-spacing:-0.98px;}
#tu_144{left:35px;bottom:522px;letter-spacing:0.09px;word-spacing:0.09px;}
#tv_144{left:35px;bottom:498px;letter-spacing:0.1px;word-spacing:0.09px;}
#tw_144{left:35px;bottom:457px;letter-spacing:-0.27px;word-spacing:3.16px;}
#tx_144{left:35px;bottom:429px;letter-spacing:0.06px;word-spacing:-0.44px;}
#ty_144{left:35px;bottom:405px;letter-spacing:0.13px;word-spacing:0.06px;}
#tz_144{left:528px;bottom:413px;}
#t10_144{left:35px;bottom:382px;letter-spacing:0.04px;word-spacing:0.14px;}
#t11_144{left:35px;bottom:359px;letter-spacing:-0.02px;word-spacing:0.21px;}
#t12_144{left:504px;bottom:367px;}
#t13_144{left:521px;bottom:359px;letter-spacing:0.07px;word-spacing:0.12px;}
#t14_144{left:35px;bottom:336px;letter-spacing:0.07px;word-spacing:0.01px;}
#t15_144{left:35px;bottom:313px;letter-spacing:0.01px;word-spacing:0.18px;}
#t16_144{left:167px;bottom:320px;}
#t17_144{left:185px;bottom:313px;letter-spacing:0.16px;word-spacing:0.03px;}
#t18_144{left:35px;bottom:289px;letter-spacing:0.04px;word-spacing:0.14px;}
#t19_144{left:504px;bottom:297px;}
#t1a_144{left:521px;bottom:289px;letter-spacing:0.12px;word-spacing:0.06px;}
#t1b_144{left:35px;bottom:266px;letter-spacing:0.08px;word-spacing:-0.95px;}
#t1c_144{left:35px;bottom:243px;letter-spacing:0.09px;word-spacing:0.1px;}
#t1d_144{left:142px;bottom:250px;}
#t1e_144{left:159px;bottom:243px;letter-spacing:0.13px;word-spacing:0.05px;}
#t1f_144{left:35px;bottom:220px;letter-spacing:0.04px;word-spacing:0.15px;}
#t1g_144{left:35px;bottom:196px;letter-spacing:0.15px;word-spacing:0.04px;}
#t1h_144{left:291px;bottom:204px;}
#t1i_144{left:324px;bottom:196px;letter-spacing:0.02px;word-spacing:0.17px;}
#t1j_144{left:35px;bottom:173px;letter-spacing:0.21px;word-spacing:-0.95px;}
#t1k_144{left:240px;bottom:181px;letter-spacing:-0.21px;}
#t1l_144{left:260px;bottom:173px;letter-spacing:0.08px;word-spacing:-0.2px;}
#t1m_144{left:35px;bottom:150px;letter-spacing:0.08px;word-spacing:0.1px;}
#t1n_144{left:522px;bottom:158px;letter-spacing:0.15px;}
#t1o_144{left:555px;bottom:150px;letter-spacing:-0.1px;}
#t1p_144{left:35px;bottom:127px;letter-spacing:0.17px;word-spacing:0.02px;}
#t1q_144{left:473px;bottom:134px;letter-spacing:0.22px;}
#t1r_144{left:526px;bottom:127px;letter-spacing:-0.1px;word-spacing:0.28px;}
#t1s_144{left:35px;bottom:104px;letter-spacing:0.06px;word-spacing:0.12px;}
#t1t_144{left:402px;bottom:111px;letter-spacing:0.2px;}
#t1u_144{left:429px;bottom:104px;letter-spacing:0.13px;word-spacing:0.06px;}
#t1v_144{left:35px;bottom:80px;letter-spacing:0.13px;word-spacing:0.06px;}
#t1w_144{left:35px;bottom:57px;letter-spacing:0.04px;word-spacing:0.14px;}
#t1x_144{left:334px;bottom:65px;}
#t1y_144{left:345px;bottom:57px;letter-spacing:0.18px;word-spacing:0.01px;}
#t1z_144{left:618px;bottom:777px;letter-spacing:0.08px;word-spacing:0.1px;}
#t20_144{left:618px;bottom:754px;letter-spacing:0.03px;word-spacing:0.15px;}
#t21_144{left:856px;bottom:761px;letter-spacing:0.08px;}
#t22_144{left:904px;bottom:754px;letter-spacing:0.1px;word-spacing:0.09px;}
#t23_144{left:618px;bottom:731px;letter-spacing:0.15px;word-spacing:0.04px;}
#t24_144{left:618px;bottom:707px;letter-spacing:0.1px;word-spacing:0.08px;}
#t25_144{left:618px;bottom:684px;word-spacing:-0.78px;}
#t26_144{left:618px;bottom:661px;letter-spacing:0.15px;word-spacing:0.04px;}
#t27_144{left:618px;bottom:638px;letter-spacing:0.13px;word-spacing:-0.44px;}
#t28_144{left:618px;bottom:614px;letter-spacing:0.19px;word-spacing:-0.24px;}
#t29_144{left:618px;bottom:591px;letter-spacing:0.07px;word-spacing:0.11px;}
#t2a_144{left:618px;bottom:568px;letter-spacing:0.04px;word-spacing:0.15px;}
#t2b_144{left:1058px;bottom:576px;}
#t2c_144{left:618px;bottom:529px;word-spacing:0.19px;}
#t2d_144{left:618px;bottom:506px;letter-spacing:0.09px;word-spacing:-1.13px;}
#t2e_144{left:618px;bottom:482px;letter-spacing:0.04px;word-spacing:0.15px;}
#t2f_144{left:618px;bottom:459px;letter-spacing:0.02px;word-spacing:0.17px;}
#t2g_144{left:1140px;bottom:459px;}
#t2h_144{left:1156px;bottom:459px;}
#t2i_144{left:618px;bottom:436px;letter-spacing:0.31px;}
#t2j_144{left:664px;bottom:444px;}
#t2k_144{left:681px;bottom:436px;letter-spacing:0.08px;word-spacing:0.1px;}
#t2l_144{left:618px;bottom:413px;letter-spacing:0.09px;word-spacing:0.1px;}
#t2m_144{left:618px;bottom:390px;letter-spacing:-0.27px;}
#t2n_144{left:667px;bottom:397px;}
#t2o_144{left:684px;bottom:390px;letter-spacing:0.07px;word-spacing:0.11px;}
#t2p_144{left:618px;bottom:366px;letter-spacing:0.19px;}
#t2q_144{left:618px;bottom:343px;letter-spacing:0.06px;word-spacing:-0.73px;}
#t2r_144{left:618px;bottom:320px;letter-spacing:0.08px;word-spacing:0.11px;}
#t2s_144{left:618px;bottom:297px;letter-spacing:0.02px;word-spacing:-0.92px;}
#t2t_144{left:618px;bottom:273px;letter-spacing:0.04px;word-spacing:-1.09px;}
#t2u_144{left:618px;bottom:250px;letter-spacing:-0.11px;word-spacing:1.52px;}
#t2v_144{left:720px;bottom:258px;}
#t2w_144{left:752px;bottom:250px;letter-spacing:0.11px;word-spacing:-0.8px;}
#t2x_144{left:618px;bottom:227px;letter-spacing:0.12px;word-spacing:0.08px;}
#t2y_144{left:618px;bottom:204px;letter-spacing:0.13px;word-spacing:0.06px;}
#t2z_144{left:618px;bottom:163px;letter-spacing:-0.01px;word-spacing:0.21px;}
#t30_144{left:618px;bottom:140px;letter-spacing:0.04px;word-spacing:0.14px;}
#t31_144{left:618px;bottom:117px;letter-spacing:0.13px;word-spacing:0.06px;}
#t32_144{left:618px;bottom:94px;letter-spacing:0.09px;}
#t33_144{left:676px;bottom:101px;letter-spacing:0.08px;}
#t34_144{left:725px;bottom:94px;letter-spacing:0.12px;word-spacing:0.06px;}
#t35_144{left:618px;bottom:71px;letter-spacing:0.06px;word-spacing:0.12px;}
#t36_144{left:933px;bottom:78px;letter-spacing:0.17px;}
#t37_144{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_144{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_144{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_144{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_144{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_144{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_144{font-size:17px;font-family:Arial-ItalicMT_kb;color:#000;}
.s6_144{font-size:20px;font-family:Arial-BoldMT_5te;color:#000;}
.s7_144{font-size:11px;font-family:ArialMT_5tg;color:#000;}
.s8_144{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts144" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg144Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg144" style="-webkit-user-select: none;"><object width="1210" height="935" data="144/144.svg" type="image/svg+xml" id="pdf144" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_144" class="t s0_144">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_144" class="t s1_144">© </span>
<span id="t3_144" class="t s0_144">(NCCN </span>
<span id="t4_144" class="t s1_144">© </span>
<span id="t5_144" class="t s0_144">), All rights reserved. NCCN Guidelines </span>
<span id="t6_144" class="t s1_144">® </span>
<span id="t7_144" class="t s0_144">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_144" class="t s2_144">NCCN Guidelines Version 4.2024 </span>
<span id="t9_144" class="t s2_144">Head and Neck Cancers </span>
<span id="ta_144" class="t s3_144">MS-3 </span>
<span id="tb_144" class="t s4_144">Guidelines incorporate non-gendered language, instead focusing on </span>
<span id="tc_144" class="t s4_144">organ-specific recommendations. This language is both more accurate </span>
<span id="td_144" class="t s4_144">and more inclusive and can help fully address the needs of individuals of </span>
<span id="te_144" class="t s4_144">all sexual orientations and gender identities. NCCN Guidelines will </span>
<span id="tf_144" class="t s4_144">continue to use the terms </span><span id="tg_144" class="t s5_144">men</span><span id="th_144" class="t s4_144">, </span><span id="ti_144" class="t s5_144">women</span><span id="tj_144" class="t s4_144">, </span><span id="tk_144" class="t s5_144">female</span><span id="tl_144" class="t s4_144">, and </span><span id="tm_144" class="t s5_144">male </span><span id="tn_144" class="t s4_144">when citing </span>
<span id="to_144" class="t s4_144">statistics, recommendations, or data from organizations or sources that do </span>
<span id="tp_144" class="t s4_144">not use inclusive terms. Most studies do not report how sex and gender </span>
<span id="tq_144" class="t s4_144">data are collected and use these terms interchangeably or inconsistently. </span>
<span id="tr_144" class="t s4_144">If sources do not differentiate gender from sex assigned at birth or organs </span>
<span id="ts_144" class="t s4_144">present, the information is presumed to predominantly represent cisgender </span>
<span id="tt_144" class="t s4_144">individuals. NCCN encourages researchers to collect more specific data in </span>
<span id="tu_144" class="t s4_144">future studies and organizations to use more inclusive and accurate </span>
<span id="tv_144" class="t s4_144">language in their future analyses. </span>
<span id="tw_144" class="t s6_144">Human Papillomavirus Infection </span>
<span id="tx_144" class="t s4_144">HPV infection is a predominant cause of squamous cell carcinomas of the </span>
<span id="ty_144" class="t s4_144">oropharynx (particularly cancers of the tonsils and tongue base). </span>
<span id="tz_144" class="t s7_144">2-9 </span>
<span id="t10_144" class="t s4_144">However, small subsets of squamous cell carcinomas of the oral cavity, </span>
<span id="t11_144" class="t s4_144">larynx, nasopharynx, and paranasal sinuses are HPV positive, </span>
<span id="t12_144" class="t s7_144">10 </span>
<span id="t13_144" class="t s4_144">and 50% </span>
<span id="t14_144" class="t s4_144">of patients with squamous cell carcinoma of unknown primary in the H&amp;N </span>
<span id="t15_144" class="t s4_144">are HPV positive. </span>
<span id="t16_144" class="t s7_144">11 </span>
<span id="t17_144" class="t s4_144">The overall incidence of HPV-positive oropharynx </span>
<span id="t18_144" class="t s4_144">cancers is increasing in the United States, particularly in men, </span>
<span id="t19_144" class="t s7_144">12 </span>
<span id="t1a_144" class="t s4_144">while the </span>
<span id="t1b_144" class="t s4_144">incidence of HPV-negative (primarily tobacco- and alcohol-related) cancer </span>
<span id="t1c_144" class="t s4_144">is decreasing. </span>
<span id="t1d_144" class="t s7_144">13 </span>
<span id="t1e_144" class="t s4_144">The attributable fraction for HPV in newly diagnosed </span>
<span id="t1f_144" class="t s4_144">oropharyngeal cancer is estimated as 60% to 70% in the United States </span>
<span id="t1g_144" class="t s4_144">and parts of the European Union. </span>
<span id="t1h_144" class="t s7_144">13-17 </span>
<span id="t1i_144" class="t s4_144">Patients with HPV-positive cancer </span>
<span id="t1j_144" class="t s4_144">have tended to be younger </span>
<span id="t1k_144" class="t s7_144">9,18 </span>
<span id="t1l_144" class="t s4_144">; however, HPV-positive oropharynx cancer </span>
<span id="t1m_144" class="t s4_144">rates are rising among older adults as the exposed cohorts age. </span>
<span id="t1n_144" class="t s7_144">19,20 </span>
<span id="t1o_144" class="t s4_144">Oral </span>
<span id="t1p_144" class="t s4_144">HPV16 infection increases the risk of oropharynx cancer, </span>
<span id="t1q_144" class="t s7_144">2,8,21,22 </span>
<span id="t1r_144" class="t s4_144">and a </span>
<span id="t1s_144" class="t s4_144">strong causal relationship has been established. </span>
<span id="t1t_144" class="t s7_144">2,21 </span>
<span id="t1u_144" class="t s4_144">HPV16 accounts for </span>
<span id="t1v_144" class="t s4_144">~90% of cases, and HPV18, 33, and 35 are responsible for the vast </span>
<span id="t1w_144" class="t s4_144">majority of the small remaining fraction. </span>
<span id="t1x_144" class="t s7_144">9 </span>
<span id="t1y_144" class="t s4_144">The prevalence of HPV16 is </span>
<span id="t1z_144" class="t s4_144">higher in oropharyngeal cancer than in cervical cancer (~50%), in which </span>
<span id="t20_144" class="t s4_144">HPV18 is also highly prevalent. </span>
<span id="t21_144" class="t s7_144">14,23-25 </span>
<span id="t22_144" class="t s4_144">Expression of the HPV E6 and E7 </span>
<span id="t23_144" class="t s4_144">oncogenes inactivates the tumor suppressor proteins p53 and pRb, </span>
<span id="t24_144" class="t s4_144">respectively, which are frequently mutated in tobacco-related mucosal </span>
<span id="t25_144" class="t s4_144">squamous cell carcinomas. Inactivation of p53 and pRb promotes genomic </span>
<span id="t26_144" class="t s4_144">instability and the development of cancer and is responsible for the </span>
<span id="t27_144" class="t s4_144">upregulation of p16 protein expression, a reliable surrogate marker of the </span>
<span id="t28_144" class="t s4_144">presence of HPV DNA in these tumors. Genetic profiling of HPV-positive </span>
<span id="t29_144" class="t s4_144">cancer has demonstrated it to be genetically distinct from HPV-negative </span>
<span id="t2a_144" class="t s4_144">squamous cell carcinoma of the head and neck (SCCHN). </span>
<span id="t2b_144" class="t s7_144">26 </span>
<span id="t2c_144" class="t s4_144">Analyses from the National Health and Nutrition Examination Survey </span>
<span id="t2d_144" class="t s4_144">(2011–2014), including 2627 adults aged 18 to 33 years, showed that HPV </span>
<span id="t2e_144" class="t s4_144">vaccination was associated with reduced vaccine-type oral HPV infection </span>
<span id="t2f_144" class="t s4_144">(0.1% in vaccinated individuals vs. 1.6% in unvaccinated individuals; </span><span id="t2g_144" class="t s5_144">P </span><span id="t2h_144" class="t s4_144">= </span>
<span id="t2i_144" class="t s4_144">.008). </span>
<span id="t2j_144" class="t s7_144">27 </span>
<span id="t2k_144" class="t s4_144">Moreover, HPV vaccination in the United States has led to herd </span>
<span id="t2l_144" class="t s4_144">protection against oral HPV16, 18, 6, and 11 infections in unvaccinated </span>
<span id="t2m_144" class="t s4_144">males. </span>
<span id="t2n_144" class="t s7_144">28 </span>
<span id="t2o_144" class="t s4_144">Results of an ongoing randomized clinical trial to investigate the </span>
<span id="t2p_144" class="t s4_144">efficacy of HPV vaccines for the prevention of oral HPV infections have </span>
<span id="t2q_144" class="t s4_144">not yet been reported. While data are not yet available, the HPV types that </span>
<span id="t2r_144" class="t s4_144">cause the overwhelming majority of SCCHN are included in the HPV </span>
<span id="t2s_144" class="t s4_144">nonavalent vaccine (provides protection against nine high-risk HPV types). </span>
<span id="t2t_144" class="t s4_144">Since there is evidence that vaccination prevents HPV-related cervical and </span>
<span id="t2u_144" class="t s4_144">anal cancers, </span>
<span id="t2v_144" class="t s7_144">29-31 </span>
<span id="t2w_144" class="t s4_144">the U.S. Food and Drug Administration (FDA) expanded </span>
<span id="t2x_144" class="t s4_144">the indication for HPV vaccination to include prevention of oral HPV </span>
<span id="t2y_144" class="t s4_144">infections and related oropharyngeal cancers in 2020. </span>
<span id="t2z_144" class="t s4_144">Patients with locally advanced HPV-positive SCCHN have improved </span>
<span id="t30_144" class="t s4_144">response to treatment and survival (overall survival [OS] and </span>
<span id="t31_144" class="t s4_144">progression-free survival [PFS]) when compared with HPV-negative </span>
<span id="t32_144" class="t s4_144">tumors. </span>
<span id="t33_144" class="t s7_144">11,32-37 </span>
<span id="t34_144" class="t s4_144">Treatment response is improved in patients receiving </span>
<span id="t35_144" class="t s4_144">radiation therapy (RT) or chemoradiation. </span>
<span id="t36_144" class="t s7_144">32,38,39 </span>
<span id="t37_144" class="t s8_144">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
